Abgenix and Genentech Extend Antibody Technology Licensing Agreement
14 März 2005 - 3:01PM
PR Newswire (US)
Abgenix and Genentech Extend Antibody Technology Licensing
Agreement FREMONT, Calif., March 14 /PRNewswire-FirstCall/ --
Abgenix, Inc. (NASDAQ:ABGX) announced today that Genentech, Inc.
(NYSE:DNA) has exercised its option to extend its technology
licensing agreement with Abgenix for an additional three years.
Under the extended agreement, Genentech will have access to
Abgenix's proprietary antibody generation technology. As a
condition of exercising the option, Genentech has purchased Abgenix
common stock representing less than one percent of Abgenix's
outstanding common stock through a private placement subject to
future registration. Abgenix may also receive future milestone
payments and fees as antibody programs advance through the
collaboration, as well as future royalties on any products that may
be successfully commercialized by Genentech. "We are pleased with
Genentech's decision to extend our agreement as we feel it
demonstrates the potential of our XenoMouse(R) technology," said
Gayle Mills, Senior Vice President of Business Development at
Abgenix. "We look forward to working with Genentech to leverage our
technology to support their research and development activities."
In 1999 Genentech signed an agreement with Abgenix to license the
Abgenix technology. Under the agreement Abgenix provides Genentech
with the XenoMouse technology for use in Genentech's product
development activities. Abgenix is a biopharmaceutical company
focused on the discovery, development and manufacturing of human
therapeutic antibodies. Several antibodies generated with the
company's proprietary technology are currently in the clinical
phase of development, including the company's lead antibody
candidate, panitumumab, an antibody to the epidermal growth factor
receptor (EGFr) that is currently in pivotal clinical trials as a
third line treatment for metastatic colorectal cancer. Abgenix is
codeveloping panitumumab with Amgen, Inc. About Abgenix Abgenix is
a biopharmaceutical company focused on the discovery, development
and manufacturing of human therapeutic antibodies. The company's
antibody development platform includes a leading technology and
state-of-the- art manufacturing capabilities that enable the rapid
generation, selection and production of high affinity, fully human
antibody product candidates to a variety of disease targets.
Abgenix leverages its leadership position in human antibody
technology to build a diversified product portfolio through its own
development efforts and through the establishment of collaborations
with multiple pharmaceutical and biotechnology companies. For more
information on Abgenix, visit the company's website at
http://www.abgenix.com/. This press release contains
forward-looking statements about Abgenix's technologies, product
development activities, collaborative arrangements, projected
financial and operating results, and achievement of milestone or
similar payments or other revenues. Such statements are subject to
a number of uncertainties that could cause actual results to differ
materially from the statements made, including risks associated
with the success of clinical trials, the progress of research and
product development programs, product manufacturing, regulatory
approval processes and meeting requirements for regulatory
approval, competitive products and services, capital requirements
and the extent and breadth of Abgenix's patent portfolio, and other
factors set forth in Abgenix's public filings with the Securities
and Exchange Commission, including the risks described in Abgenix's
quarterly report on Form 10-Q for the quarter ended September 30,
2004 and annual report on Form 10-K for the year ended December 31,
2003. Abgenix is providing this information as of the date of this
press release and does not undertake any obligation to update any
forward-looking statements. DATASOURCE: Abgenix, Inc. CONTACT: Ami
Knoefler, Senior Director, Corporate Communications and Investor
Relations, of Abgenix, Inc., +1-510-284-6350, or +1-510-284-6605
Web site: http://www.abgenix.com/
Copyright
Abgenix (NASDAQ:ABGX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Abgenix (NASDAQ:ABGX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Abgenix (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Abgenix, (MM) News-Artikel